Highlights the molecular and morphological adaptations, such as increased ANP, BNP, and β-MHC expression, involved in cardiomyocyte hypertrophy.
No takes yet. Share an insight, caveat, or question.
Does not guide therapy; confirms hypertrophic markers for mechanistic studies but leaves clinical translation open.
Peter H. Sugden (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: